Treatment of drug-resistant tuberculosis in children and young adolescents in Brazil

IF 1.9 Q3 INFECTIOUS DISEASES
Fernanda Bruzadelli Paulino da Costa , Thaís Zamboni Berra , Jaqueline Garcia de Almeida Ballestero , Patricia Bartholomay Oliveira , Daniele Maria Pelissari , Yan Mathias Alves , Antônio Carlos Vieira Ramos , Juliana Queiroz Rocha de Paiva , Titilade Kehinde Ayandeyi Teibo , Ricardo Alexandre Arcêncio
{"title":"Treatment of drug-resistant tuberculosis in children and young adolescents in Brazil","authors":"Fernanda Bruzadelli Paulino da Costa ,&nbsp;Thaís Zamboni Berra ,&nbsp;Jaqueline Garcia de Almeida Ballestero ,&nbsp;Patricia Bartholomay Oliveira ,&nbsp;Daniele Maria Pelissari ,&nbsp;Yan Mathias Alves ,&nbsp;Antônio Carlos Vieira Ramos ,&nbsp;Juliana Queiroz Rocha de Paiva ,&nbsp;Titilade Kehinde Ayandeyi Teibo ,&nbsp;Ricardo Alexandre Arcêncio","doi":"10.1016/j.jctube.2023.100388","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Drug-resistant tuberculosis (DR-TB) is a global threat and a challenge for public health authorities worldwide. In children, the diagnosis is even more challenging and DR-TB is poorly described in the literature, as are its treatment outcomes. In this study, we aimed to describe the treatment of drug-resistant TB in children and young adolescents in Brazil.</p></div><div><h3>Methods</h3><p>A descriptive epidemiological study of treatment for DR-TB in children under 15 years of age in Brazil between 2013 and 2020. The primary data source was the Information System for Special Tuberculosis Treatments (SITE-TB). Categorical variables were analyzed using relative frequencies (%) and continuous variables by measures of central tendency to characterize the profile of the cases, namely: sociodemographic, clinical characteristics, procedures, tests performed and treatment success. In order to verify the distribution of cases, a spatial analysis was carried out based on the municipality where the cases resided.</p></div><div><h3>Results</h3><p>Between 2013 and 2020, 19,757 tuberculosis (TB) cases occurred in children aged &lt;15 years in Brazil, and 46 cases of treatment for DR-TB were reported during the same period (annual average of 6 cases). Of these, 73.9% were aged 10–14, 65.2% were male, 4.3% were HIV+ and 43.3% were underweight (BMI&lt;18.5) at the start of treatment. 17.4% had previous contact with TB, 69.6% had primary resistance, 47.8% multidrug resistance. The median duration of treatment was 15 months. DOT and standardized treatment regimen were performed in 52.2% of cases. Bacilloscopy was performed for 97.8% (57.8% positive); culture for 89.1% (75.6% positive), rapid molecular test for 73.9% with proven resistance to rifampicin in 55.8%. Susceptibility testing revealed resistance mainly to isoniazid (87.8%) and rifampicin (60.6%). 73.9% of cases were successfully treated and one death was reported. Cases were treated in 26 Brazilian municipalities, with the majority in Rio de Janeiro (15) and São Paulo (4).</p></div><div><h3>Conclusion</h3><p>DR-TB treatment was recorded in &lt;1% of general TB cases in children and young adolescents, suggesting underreporting of drug-resistant cases in the country. Despite the low number of registered cases, the data reflect the situation of DR-TB in this population and describe important aspects of the problem, as the child needs comprehensive, individualized care, with support from different professionals. We recommend a strengthening of the country's referral services for the care of children with DR-TB so that surveillance and health care services can work together to identify and follow up cases.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"33 ","pages":"Article 100388"},"PeriodicalIF":1.9000,"publicationDate":"2023-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/b9/main.PMC10425933.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S240557942300044X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Drug-resistant tuberculosis (DR-TB) is a global threat and a challenge for public health authorities worldwide. In children, the diagnosis is even more challenging and DR-TB is poorly described in the literature, as are its treatment outcomes. In this study, we aimed to describe the treatment of drug-resistant TB in children and young adolescents in Brazil.

Methods

A descriptive epidemiological study of treatment for DR-TB in children under 15 years of age in Brazil between 2013 and 2020. The primary data source was the Information System for Special Tuberculosis Treatments (SITE-TB). Categorical variables were analyzed using relative frequencies (%) and continuous variables by measures of central tendency to characterize the profile of the cases, namely: sociodemographic, clinical characteristics, procedures, tests performed and treatment success. In order to verify the distribution of cases, a spatial analysis was carried out based on the municipality where the cases resided.

Results

Between 2013 and 2020, 19,757 tuberculosis (TB) cases occurred in children aged <15 years in Brazil, and 46 cases of treatment for DR-TB were reported during the same period (annual average of 6 cases). Of these, 73.9% were aged 10–14, 65.2% were male, 4.3% were HIV+ and 43.3% were underweight (BMI<18.5) at the start of treatment. 17.4% had previous contact with TB, 69.6% had primary resistance, 47.8% multidrug resistance. The median duration of treatment was 15 months. DOT and standardized treatment regimen were performed in 52.2% of cases. Bacilloscopy was performed for 97.8% (57.8% positive); culture for 89.1% (75.6% positive), rapid molecular test for 73.9% with proven resistance to rifampicin in 55.8%. Susceptibility testing revealed resistance mainly to isoniazid (87.8%) and rifampicin (60.6%). 73.9% of cases were successfully treated and one death was reported. Cases were treated in 26 Brazilian municipalities, with the majority in Rio de Janeiro (15) and São Paulo (4).

Conclusion

DR-TB treatment was recorded in <1% of general TB cases in children and young adolescents, suggesting underreporting of drug-resistant cases in the country. Despite the low number of registered cases, the data reflect the situation of DR-TB in this population and describe important aspects of the problem, as the child needs comprehensive, individualized care, with support from different professionals. We recommend a strengthening of the country's referral services for the care of children with DR-TB so that surveillance and health care services can work together to identify and follow up cases.

Abstract Image

Abstract Image

巴西儿童和青少年耐药结核病的治疗
引言耐药结核病(DR-TB)是一个全球性的威胁,也是世界各地公共卫生当局面临的挑战。在儿童中,诊断更具挑战性,文献中对DR-TB及其治疗结果的描述很少。在这项研究中,我们旨在描述巴西儿童和青少年耐药结核病的治疗。方法2013年至2020年巴西15岁以下儿童DR-TB治疗的描述性流行病学研究。主要数据来源是结核病特殊治疗信息系统。使用相对频率(%)和连续变量分析分类变量,通过测量中心趋势来表征病例的特征,即:社会人口统计学、临床特征、程序、测试和治疗成功率。为了核实病例的分布情况,根据病例居住的市镇进行了空间分析。结果2013年至2020年间,19757例结核病病例发生在<;巴西15年,同期报告了46例DR-TB治疗病例(年均6例)。其中,73.9%的患者年龄在10-14岁之间,65.2%的患者为男性,4.3%的患者为艾滋病毒携带者,43.3%的患者在治疗开始时体重不足(BMI<18.5)。17.4%以前接触过结核病,69.6%有原发耐药性,47.8%有多药耐药性。治疗的中位持续时间为15个月。52.2%的病例采用DOT和标准化治疗方案。细菌镜检查阳性率为97.8%(57.8%);培养89.1%(75.6%阳性),快速分子检测73.9%,对利福平的耐药性为55.8%。药敏试验显示主要对异烟肼(87.8%)和利福平(60.6%)有耐药性。73.9%的病例成功治疗,1例死亡。在巴西26个城市治疗了病例,其中里约热内卢(15个)和圣保罗(4个)占多数;1%的一般结核病病例发生在儿童和青少年中,这表明该国对耐药病例的报告不足。尽管登记病例数量较低,但数据反映了该人群中DR-TB的情况,并描述了问题的重要方面,因为儿童需要在不同专业人员的支持下进行全面、个性化的护理。我们建议加强该国的转诊服务,以照顾患有DR-TB的儿童,以便监测和医疗保健服务能够共同识别和跟进病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine
CiteScore
4.00
自引率
5.00%
发文量
44
审稿时长
30 weeks
期刊介绍: Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信